Abstract
Background: Isovitexin-2"-O-D-glucopyranoside (IVG) has been known to exhibit sedative and hypnotic effects. However, there is little understanding of the in vivo pharmacokinetics and tissue distribution of IVG.
Objective: This study aimed to investigate the pharmacokinetics and tissue distribution of IVG.
Methods: The study employed an HPLC–ESI-MS/MS method to analyze the pharmacokinetics and tissue distribution of IVG. Results: Under mass spectrometry, IVG and internal standard (IS) showed strong negative ionization signals. MRM analysis chose ion transitions m/z 593.3 → 293.0 (IVG) and m/z 579.8 → 271.4 (IS). Method validation indicated high precision, accuracy, and reliability with a quantitation limit under 20 ng/mL. After intravenously administering 5.0 mg/kg of IVG, rapid clearance from rat plasma was observed, with a half-life (t1/2) of 3.49 ± 0.99 h and a clearance rate of 54.53 ± 11.90 mL/kg/h. The area under the curve (AUC0-12h) of 37.79 ± 7.65 μg·h/mL indicated a brisk metabolic rate. Evaluating the tissue distribution, the highest accumulation was seen in the liver (30.32 ± 3.06 μg/g), followed by the kidney (20.58 ± 2.12 μg/g) and intestine (6.69 ± 0.93 μg/g), suggesting a propensity for IVG to concentrate in these tissues. Importantly, the presence of IVG in the brain underlines its potential to traverse the blood-brain barrier. These findings revealed that following intravenous administration, IVG was swiftly and broadly distributed throughout various rat tissues.
Conclusion: This study provides valuable information on the pharmacokinetics and tissue distribution of IVG, implicating its potential as a novel and effective drug candidate for sedative and anxiolytic treatment.
Graphical Abstract
[http://dx.doi.org/10.1007/s11101-020-09709-1]
[http://dx.doi.org/10.1016/j.phymed.2009.07.004] [PMID: 19682877]
[http://dx.doi.org/10.1080/14786410701192827] [PMID: 17479419]
[http://dx.doi.org/10.4062/biomolther.2014.110] [PMID: 25767684]
[http://dx.doi.org/10.1016/j.pbb.2014.11.003] [PMID: 25449359]
[http://dx.doi.org/10.1016/j.jep.2019.111886] [PMID: 31026552]
[http://dx.doi.org/10.1055/s-2005-871287] [PMID: 16142640]
[http://dx.doi.org/10.4103/0973-1296.75899] [PMID: 21472077]
[http://dx.doi.org/10.1016/S0040-4020(00)00842-5]
[http://dx.doi.org/10.1080/10286020.2011.637491] [PMID: 22296152]
[http://dx.doi.org/10.3724/SP.J.1009.2009.00047]
[http://dx.doi.org/10.1080/10286021003752284] [PMID: 20419541]
[http://dx.doi.org/10.1016/j.phymed.2016.06.015] [PMID: 27444348]
[http://dx.doi.org/10.1016/j.jpba.2016.01.005] [PMID: 26780157]
[http://dx.doi.org/10.1093/chromsci/bmt100] [PMID: 23828910]
[http://dx.doi.org/10.1016/S0378-4347(96)00088-6] [PMID: 8953186]
[http://dx.doi.org/10.1002/bmc.926] [PMID: 17939170]
[http://dx.doi.org/10.4103/2229-4708.72226] [PMID: 23781413]
[http://dx.doi.org/10.1016/j.tig.2005.12.005] [PMID: 16380191]
[http://dx.doi.org/10.4274/tjps.galenos.2021.60486] [PMID: 34979741]
[http://dx.doi.org/10.1016/j.clinbiochem.2012.01.012] [PMID: 22285385]
[http://dx.doi.org/10.1016/j.jchromb.2014.03.030] [PMID: 24747520]
[http://dx.doi.org/10.1016/j.jchromb.2013.10.025] [PMID: 24200865]
[http://dx.doi.org/10.1038/nm.3407] [PMID: 24309662]
[http://dx.doi.org/10.1007/s12975-011-0125-x] [PMID: 22299022]